
GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide
FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.
Summarize this article with
In this article
- 01How to Get GLP-1 Agonists for Weight Loss in 2026, 5 Steps
- 02How Do GLP-1 Medications Work?
- 03Which GLP-1 Medications Are FDA-Approved for Weight Loss?
- 04How Much Weight Can You Lose on GLP-1 Medications?
- 05What Are the Side Effects?
- 06Who Qualifies for GLP-1 Medications?
- 07How Do You Choose a GLP-1 Provider?
Verified August 2026: approved GLP-1 weight-loss labels generally use a BMI of 30+ (or 27+ with a weight-related condition), subject to the specific product label, and the approved injections produced 14.9% body weight loss for semaglutide in STEP-1 and up to 20.9% for tirzepatide in SURMOUNT-1 over 68-72 weeks. Those brand trials do not establish outcomes for compounded products. Advertised compounded paths include Embody semaglutide from $79 on a selected plan, Yucca Health at $146/month on a 6-month plan, and Enhance MD from $99 first month ($280/month after) for tirzepatide. Brand-name option: Hers lists Wegovy pill medication from $149 and the pen from $199 plus a required $39 first-month/$149 ongoing membership, making the lowest all-in path $188 initially and $298/mo ongoing. If you would rather pay one flat monthly rate than chase an intro price that steps up, how much Willow's GLP-1 costs is $299/mo with monthly provider support included.
Quick answer by priority:
- •Low advertised compounded-semaglutide floors: Embody from $79/mo on a selected plan or Yucca Health $146/mo on a 6-month plan
- •Maximum weight loss: Tirzepatide via Enhance MD compounded from $99 first month or Sprout Health compounded from $199 first month (dedicated care coordinator)
- •FDA-approved brand only: Hers lists Wegovy pill medication from $149 and the pen from $199, plus required membership ($39 first month, $149/mo ongoing); lowest all-in path $188 initially, then $298/mo
- •Non-injectable tirzepatide: Embody oral gum $329 for one month, dissolvable tirzepatide, no injection, no fasting required. Prepaying six months works out to $309/mo, against the injectable GLP-1 + GIP floor advertised from $129 on a selected plan.
- •Pill (no injection): Foundayo from $149/mo (orforglipron, 12.4% in ATTAIN-1) or NovoCare oral Wegovy from $149/mo, dose-dependent (16.6% in OASIS; separate trial)
- •Medicare: Coverage is live as of July 2026 at $50/mo copay. See Medicare Part D guide.
- •Undecided: Take the 60-second match quiz.
This guide covers eligibility, medication selection, cost breakdown by insurance status, side effects, and the full 5-step telehealth process, all based on FDA prescribing information, published trial data, and verified pricing from all 54 telehealth providers we track.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality. The cheapest we track right now is $69/mo.
Compare all 54 GLP-1 providers →How to Get GLP-1 Agonists for Weight Loss in 2026, 5 Steps
Here's the exact process for getting GLP-1 agonists for weight loss in 2026. The whole thing takes 5-10 minutes online and medication ships within 2-7 days.
- •Step 1: Check if you qualify. FDA eligibility requires a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or fatty liver. Use our free eligibility checker to run the numbers in 30 seconds.
- •Step 2: Choose a medication type. The main options are brand-name injectables (Wegovy, Zepbound) at $299-$449/mo self-pay, compounded injectables at $99-$250/mo cash-pay, or oral pills (Rybelsus, Wegovy pill, Foundayo) at $149-$649/mo. Read our brand vs compounded guide to understand the tradeoffs.
- •Step 3: Pick a telehealth provider. Our rankings compare 54 GLP-1 telehealth programs; availability varies by state. Advertised entry points include Embody (compounded semaglutide from $79 on a selected plan), Enhance MD ($49 first month compounded semaglutide, $99 first month compounded tirzepatide), and Hers (Wegovy pill medication from $149 or pen from $199, plus required $39 first-month/$149 ongoing membership). Compare renewal rates and line items in our full cheapest ranking, or take the match quiz.
- •Step 4: Complete the online medical intake. Every reputable provider requires a health questionnaire covering your medical history, current medications, and weight loss goals. Most accept async intake (no video call needed) and approve within 24-72 hours. Some providers like Shed ship within 2-3 days of signup.
- •Step 5: Start treatment. Medication ships directly to your home. You'll self-inject once weekly (for injectables) or take a daily pill (for orals) at the lowest starting dose. Dose escalation happens over 16-20 weeks. Read our first month on GLP-1 guide for a week-by-week timeline.
Join the list for the GLP-1 Letter.
We re-verify every price on this site against the provider's own live page and check every program against the FDA warning letter database. Join the list and you will hear from us when that work turns up something worth an email. No promised schedule until we are actually keeping one. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
How Do GLP-1 Medications Work?
GLP-1 receptor agonists are synthetic versions of a gut hormone called glucagon-like peptide-1 (GLP-1) that your body naturally produces after eating. They work through three distinct mechanisms:
- •Appetite suppression: They act on GLP-1 receptors in the hypothalamus, your brain's satiety center, reducing hunger signals. They also lower ghrelin (the "hunger hormone") and increase fullness hormones like peptide YY.
- •Delayed gastric emptying: They slow how quickly food leaves your stomach, keeping you feeling full longer after meals.
- •Glucose regulation: They stimulate insulin release and suppress glucagon from the pancreas, which is why they were originally developed for Type 2 diabetes.
Tirzepatide (sold as Zepbound and Mounjaro) takes this further, it's a dual GIP/GLP-1 receptor agonist, activating two different incretin receptors simultaneously. This dual mechanism may explain why tirzepatide consistently shows higher weight loss numbers in clinical trials.
Which GLP-1 Medications Are FDA-Approved for Weight Loss?
As of April 2026, the following GLP-1 receptor agonists are FDA-approved specifically for chronic weight management:
| Medication | Brand | Dosing | Approved |
|---|---|---|---|
| Orforglipron 3-17.2mg tablet | Foundayo | Daily pill (no food restrictions) | Apr 2026 |
| Semaglutide 25mg oral | Wegovy (pill) | Daily tablet (fasting required) | Dec 2025 |
| Tirzepatide injection | Zepbound | Weekly injection | Nov 2023 |
| Semaglutide 2.4mg injection | Wegovy | Weekly injection | June 2021 |
| Liraglutide 3.0mg injection | Saxenda | Daily injection | Dec 2014 |
| Generic liraglutide (Teva) | Generic Saxenda | Daily injection | Aug 2025 |
Ozempic and Mounjaro are FDA-approved only for Type 2 diabetes, not weight loss. However, doctors can and do prescribe them off-label for weight management. If your provider prescribes Ozempic instead of Wegovy, this is legal but your insurance may not cover it for weight loss.
Editor's Top Pick
Embody
from $69/mo · 7.3/10 · Compounded
Online weight-loss program that ships compounded GLP-1 medication to your door. Modern Metabolic Medicine, Inc. runs the storefront and OpenLoop Health supplies the clinical network on the current site. Embody now advertises compounded semaglutide from $79 and GLP-1 + GIP from $129; its FAQ says the chosen rate holds within a selected 4-, 12-, 24- or 52-week plan. Its standout is oral tirzepatide gum for people who do not want injections.
How Much Weight Can You Lose on GLP-1 Medications?
The weight loss numbers from major clinical trials are significant. These are averages from large, placebo-controlled studies published in peer-reviewed journals like the New England Journal of Medicine.
| Trial | Medication | Duration | Avg Weight Loss |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg | 68 weeks | -14.9% body weight |
| STEP 5 | Semaglutide 2.4mg | 104 weeks (2 yr) | -16.7% |
| STEP UP | Semaglutide 7.2mg | 68 weeks | -20.7% |
| OASIS 4 | Oral semaglutide 25mg | 64 weeks | -13.6% |
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | -22.5% |
| SURMOUNT-5 | Tirzepatide vs Semaglutide | 72 weeks | -20.2% vs -13.7% |
In the STEP 1 trial, about 86% of participants on semaglutide 2.4mg achieved at least 5% weight loss, and roughly 51-64% lost 15% or more. In SURMOUNT-1, 96% of participants on the 15mg tirzepatide dose achieved at least 5% weight loss, and 36% lost more than 25% of their body weight.
The head-to-head SURMOUNT-5 trial (published May 2025 in NEJM) showed tirzepatide produced significantly greater weight loss than semaglutide at maximum doses, 20.2% vs 13.7%. Tirzepatide also had a lower rate of GI-related discontinuation (2.7% vs 5.6%).
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 54 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizWhat Are the Side Effects?
GI side effects are the most common issue. From the Wegovy prescribing information and STEP trials:
| Side Effect | Wegovy | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 25% | 6% |
| Constipation | 24% | 11% |
| Abdominal pain | 20% | 11% |
The key insight: 98.1% of GI side effects were mild-to-moderate. Only 4.1% of Wegovy patients reported severe GI reactions. Side effects are worst during dose escalation (the first few weeks at each new dose level) and generally decrease over time. Both medications use gradual dose-titration schedules specifically to minimize these effects.
Who Qualifies for GLP-1 Medications?
The FDA-approved eligibility criteria for GLP-1 weight loss medications:
- •BMI of 30 or higher (obesity), OR
- •BMI of 27 or higher (overweight) with at least one weight-related health condition
Qualifying comorbidities include Type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, sleep apnea, non-alcoholic fatty liver disease (NAFLD), and PCOS, among others.
Wegovy is also approved for patients aged 12 and older with obesity. Insurance companies may apply stricter criteria, some require a BMI of 35+, documented failed diet/exercise attempts, or prior authorization.
How Do You Choose a GLP-1 Provider?
Most GLP-1 prescriptions in 2026 come through telehealth platforms. When evaluating providers, consider:
- •Medication options: Do they offer both brand-name and compounded? Brand-only? Only compounded?
- •Clinical support: Is there ongoing physician oversight, or just an initial consultation?
- •Insurance: Do they accept your insurance, or is it cash-pay only?
- •Total cost: Monthly medication cost plus any consultation, lab work, or membership fees.
- •Dose titration: Do they follow standard dose escalation schedules?
Fit and total cost can pull in different directions. AgelessRx, for example, combines compounded GLP-1 options with a broader longevity-treatment menu, but its published medication prices carry a separate $50/month clinical-oversight fee. That is why the complete care model matters more than the medication headline alone.
We independently evaluate and rank 54 telehealth GLP-1 providers on our homepage. Check our rankings or take our quiz to find the best match for your budget and preferences.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Find your GLP-1 program, our Top Pick is Embody
Our featured pick, drawn from our independent ranking of 54 providers, is listed at from $69/mo.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 54 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
Saw Medicare mentioned in "GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide"? Here's exactly what's covered, who qualifies, and how the $50/mo Bridge copay works from July 1, 2026.
Read the Medicare Coverage Guide →IvyRx GLP-1 Review 2026: Flat-Rate Compounded Semaglutide & Tirzepatide at $175 to $297/mo
ComparisonsMounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For
Cost & InsuranceGLP-1 Cost 2026: Wegovy, Zepbound & Ozempic Prices ($25 to $1,350/mo)
Keep exploring
- →Provider Rankings
- →Cheapest Providers
- →Take the Match Quiz
- →Weight Loss Predictor
- →Full Cost Guide
- →Cost Calculator
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss, which in turn lowers the risk of many weight-related conditions. These treatments also improve patients' quality of life in a meaningful way, making this a genuine win, win.”
“It's the first time that we have seen this magnitude of weight loss compared to current medications on the market for obesity. It's 1.5 to 2.5 times more effective than currently available drugs.”
“Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before. The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.